Aria Diagnostics Snares $50M Series C

Aria Diagnostics (formerly Tandem Diagnostics), a molecular diagnostics company, announced today that it has secured more than $50 million in oversubscribed Series C funding. New investors include Meritech Capital Partners and a leading mutual fund group. They will join existing Venrock and Domain Associates investors. The company is developing a targeted approach to cell-free DNA (cfDNA) analysis in maternal blood to provide a safe, highly accurate and affordable test for pregnant women. Aria will use the funds to support product development and prepare for the commercialization of its proprietary prenatal test to detect common fetal trisomies such as Trisomy 21, which is associated with Down syndrome.

The company is led by industry veterans including John Stuelpnagel, DVM, who serves as CEO and formerly COO and co-founder of Illumina, Inc. Ken Song, MD, Chief Executive Officer of Aria Diagnostics, will present Jan at the upcoming 30th JP Morgan Annual Healthcare Conference. 12, 2012 at 8:30 a.m. Oh, m

In addition, Aria’s laboratory facility in San Jose, California , received the initial Clinical Laboratory Improvement Amendment (CLIA) certification. Administered by the Centers for Medicare & Medicaid Services (CMS), CLIA establishes quality standards for all laboratory tests to ensure the accuracy, reliability and timeliness of patient test results.

“Aria is positioned to be an outstanding performer, as our name suggests, as we seek to improve the way in which cfDNA can be analyzed to identify the risk of genetic disorders in the fetus,” Song said. “We are encouraged by the interest in our company and the strong financial support that we have received, and the initial CLIA certification brings us one step closer to delivering a simple, objective blood test that will benefit pregnant women and their healthcare providers. “That’s right.

Traditional prenatal testing options are limited and have significant drawbacks as they may be complicated, both for the health care provider and the patient, and may also expose the mother and the fetus to potential harm. Aria is currently conducting clinical studies to evaluate the performance of its blood test in the detection of fetal chromosome conditions in pregnant women, with the first peer-reviewed data published online by Jan. 6, 2012 Prenatal Diagnosis

About Aria Diagnosis (formerly Tandem Diagnosis)

Diagnostics Aria, Inc. , is a molecular diagnostic company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Aria uses its proprietary technology to conduct a targeted analysis of cell-free DNA in the blood. Aria’s simple blood test equips pregnant women and their health care providers with reliable information to make decisions about their health without creating unnecessary stress or anxiety.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Aria%20Diagnostics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co